<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976543</url>
  </required_header>
  <id_info>
    <org_study_id>20200202-Qilu</org_study_id>
    <nct_id>NCT04976543</nct_id>
  </id_info>
  <brief_title>Safety of Anticoagulant Therapy After Variceal Band Ligation</brief_title>
  <official_title>Safety of Anticoagulant Therapy After Variceal Band Ligation in Cirrhotic Variceal Bleeding Patients With Portal Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jinan Military General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaocheng People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study is aimed to clarify the safety of anticoagulant therapy after variceal band&#xD;
      ligation for cirrhotic variceal bleeding patients with portal vein thrombosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variceal bleeding is one of the most serious complications of liver cirrhosis and is&#xD;
      associated with significant morbidity and mortality. Portal vein thrombosis (PVT) aggravates&#xD;
      portal hypertension and worsens hemorrhage, which Increases the risk of endoscopic therapy,&#xD;
      and PVT has been shown to be associated with a longer time to variceal eradication, a higher&#xD;
      risk of variceal relapse and rebleeding. So, PVT should be treated earlier. Anticoagulant&#xD;
      therapy is the main therapy but its safety is unkown，especially for variceal bleeding&#xD;
      patients who have undergone variceal band ligation. Our purpose is to clarify its safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">July 12, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rebleeding</measure>
    <time_frame>6-week</time_frame>
    <description>a new hematemesis or melaena after a period of 24h of stable vital signs and hemoglobin levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>6-week</time_frame>
    <description>death from all causes of illness related to liver dysfunction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Vein Thrombosis</condition>
  <condition>Esophageal Varices</condition>
  <arm_group>
    <arm_group_label>Anticoagulation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low molecular weight heparin subcutaneously every 12ths for 6 months or for 14 days followed by warfarin orally with a initial dosage of 3mg daily for 5.5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no anticoagulation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight heparin and/or warfarin</intervention_name>
    <description>low molecular weight heparin and/or warfarin was given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.</description>
    <arm_group_label>Anticoagulation group</arm_group_label>
    <other_name>anticoagulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical diagnosis of cirrhosis&#xD;
&#xD;
          -  Portal hypertension with esophageal variceal bleeding&#xD;
&#xD;
          -  diagnosis of PVT by imaging examination&#xD;
&#xD;
          -  undergo variceal band ligation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  liver cancer or other tumors&#xD;
&#xD;
          -  cavernous transformation of portal vein&#xD;
&#xD;
          -  creatinine more than 20mg/dL，platelet count lower than 10*10^9/L&#xD;
&#xD;
          -  ongoing antithrombotic treatment or have received thrombolytic treatment&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  Having contraindications for endoscopic therapy&#xD;
&#xD;
          -  Severe heart and lung diseases，uncontrolled massive hemorrhage or general infection&#xD;
&#xD;
          -  major surgery within 3 months&#xD;
&#xD;
          -  primary thrombophilia, Budd-Chiari syndrome&#xD;
&#xD;
          -  Having received endoscopic therapy, transjugular intrahepatic portosystemic shunt&#xD;
             (TIPS) or liver transplantation before&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanjing Gao, PhD.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital, Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology,Qilu Hospital,Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endoscopic therapy</keyword>
  <keyword>endoscopic variceal band ligation</keyword>
  <keyword>low molecular weight heparin</keyword>
  <keyword>warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

